Clinically supported testing timeframes

One of the key advantages of biomarker-based evaluation is its extended testing window relative to many conventional TBI assessment tools. While the optimal window for assessing the broadest range of biomarkers is generally approximately 30 days to 12 weeks post-injury, clinically meaningful results may still be obtained well beyond the acute period. Depending on the specific biomarkers ordered, the laboratory’s validated cutoffs, and the clinical question being addressed, certain biomarkers may provide informative findings months or even years after injury, including up to ~5 years post-injury.

Through specialist-supported workflows, treating providers may access biomarkers appropriate for evaluation across multiple phases of injury and recovery. The clinical relevance and interpretive value of specific biomarkers vary based on time since injury, injury characteristics, symptom course, and individual patient factors, and are determined by the treating provider with specialist support as appropriate.